For about two years, most compounded tirzepatide in the United States was made under a specific legal opening: the drug was on FDA's shortage list. This page gives the dates that opened and closed that window, from FDA's own documents, and what FDA has said since about the products.
The timeline
December 15, 2022. Tirzepatide injection products are added to FDA's drug shortage list because of demand. While a drug is on the list, section 503A pharmacies and 503B outsourcing facilities may compound versions that are essentially copies of the approved product, which is otherwise restricted.
October 2, 2024. FDA first determines that the shortage is resolved. The Outsourcing Facilities Association sues, arguing the decision was unlawful; the matter is remanded to FDA for reevaluation.
December 19, 2024. FDA issues a declaratory order confirming its determination that the tirzepatide shortage is resolved, based on a decision memorandum of the same date finding that supply meets or exceeds demand. The order states that FDA does not intend to take action against compounders for shortage-related violations for a transition period: 60 calendar days, until February 18, 2025, for pharmacies compounding under 503A, and 90 days, until March 19, 2025, for 503B outsourcing facilities. The order explains the longer period for outsourcing facilities by their larger batch production and longer lead times.
February 18, 2025. End of enforcement discretion for 503A pharmacies.
March 19, 2025. End of enforcement discretion for 503B outsourcing facilities.
FDA's order also records some product history: Mounjaro pens were approved in May 2022 and added to the shortage list in December 2022; Zepbound pens were approved in November 2023 and added to the shortage list in April 2024; Zepbound single-dose vials were approved in a supplement to NDA 217806 in March 2024 and were never on the shortage list. The agency states that it continues to monitor supply and demand.
What the order did and did not do
It removed the shortage as a basis for compounding copies of the approved tirzepatide products. It did not make compounding tirzepatide categorically unlawful; sections 503A and 503B allow compounding under other conditions, such as a documented clinical need for a formulation that differs from the approved product for an individual patient. Whether a given product fits those conditions is not something this site can assess, and the sentence you will see on every compounding-related page here is the accurate summary: compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro.
What FDA says about the products
FDA's page on unapproved GLP-1 drugs, current as of September 1, 2026, makes four points that apply to tirzepatide.
Compounded drugs are not FDA approved; FDA does not review them for safety, effectiveness or quality before they are marketed.
FDA has received adverse event reports involving compounded tirzepatide and semaglutide, including dosing errors in which patients measured and self-administered incorrect doses and in which healthcare professionals miscalculated doses. Some reports involved doses above the approved label or escalation faster than the label schedule, with nausea and vomiting as the result. The units page exists because of this paragraph.
As of May 31, 2026, FDA counted more than 730 adverse event reports for compounded tirzepatide and 990 for compounded semaglutide. Pharmacies compounding under 503A are not required to submit adverse event reports to FDA, so the agency states the numbers likely under-represent actual events.
For semaglutide, FDA has flagged salt forms (semaglutide sodium, semaglutide acetate) that differ from the approved active ingredient and whose properties FDA does not have information on. The page does not make the same salt-form point about tirzepatide, and this site does not extend it.
How this affects your choices
If you are prescribed Zepbound or Mounjaro, none of this applies to your product, and the pricing pages cover what Lilly charges for each presentation. If you are prescribed compounded tirzepatide, including through FormBlends, which is run by the same editorial team as this site, the practical consequences are the ones this site keeps repeating: the concentration on the vial is the only one that counts, the brand label's storage and timing rules do not govern your product, and the pharmacy's licence and certificate of analysis are the documents that stand in for FDA review. For the rules pharmacy by pharmacy and state by state, the network's compounding site, Compounding Explained, goes further than this page.
Questions people ask
Is compounded tirzepatide illegal now?
This site does not give legal advice. What FDA's order says is that with the shortage resolved, the shortage-based flexibility that let 503A pharmacies and 503B outsourcing facilities compound copies of Zepbound and Mounjaro ended on February 18 and March 19, 2025 respectively. Compounding remains lawful under the other conditions in sections 503A and 503B of the FD&C Act, which are narrower and patient-specific. Whether a particular pharmacy's product meets them is a question for that pharmacy and your state board.
Is compounded tirzepatide the same drug as Zepbound?
It is meant to contain the same active ingredient, but FDA has not reviewed it for safety, effectiveness or quality, it is not FDA approved, and it is not interchangeable with Zepbound or Mounjaro. Its concentration, excipients, sterility and potency depend on the pharmacy that made it.
Sources
- FDA, Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products, December 19, 2024 Accessed September 4, 2026.
- FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, current as of September 1, 2026 Accessed September 4, 2026.
- FDA: Human Drug Compounding Accessed September 4, 2026.
Canonical URL: https://formblendstirzepatide.com/guides/compounded-tirzepatide-and-the-fda. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.